TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2956427

Group type: EXPERIMENTAL
Intervention: High exercise (56% of maximum work capacity)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low exercise (28% of maximum, simulating normal daytime activity)
Number of subjects: 10
Study: 31146872

Group type: EXPERIMENTAL
Intervention: Mitral valve replacement
Number of subjects: 251

Group type: COMPARATOR
Intervention: Mitral valve repair
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Mitral valve surgery (both replacement and repair)
Number of subjects: 251
Study: 29423513

Group type: EXPERIMENTAL
Intervention: Contact lens treatment
Number of subjects: 57
Study: 27183095

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) with donor lymphocyte infusion (DLI)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Brentuximab vedotin (BV) without donor lymphocyte infusion (DLI)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV)
Number of subjects: 16
Study: 25326126

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (lap group)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Open surgery (open group)
Number of subjects: 47
Study: 22055966

Group type: EXPERIMENTAL
Intervention: Physiotherapist-supervised home visit program by non-professional home rehabilitation assistants (HRAs) for 10-14 months
Number of subjects: 417

Group type: COMPARATOR
Intervention: No home visit intervention (Control Group)
Number of subjects: 417
Study: 20444845

Group type: EXPERIMENTAL
Intervention: Immediate zoledronic acid (ZOL; 4 mg every 6 months)
Number of subjects: 1065

Group type: COMPARATOR
Intervention: Delayed zoledronic acid (initiated only for fracture or high risk thereof)
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Immediate zoledronic acid (ZOL)
Number of subjects: 1065
Study: 17880755

Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg once daily for 5 days
Number of subjects: 192

Group type: COMPARATOR
Intervention: Ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days
Number of subjects: 192
Study: 15270876

Group type: EXPERIMENTAL
Intervention: Temozolomide 150 mg m(‐2) on days 1‐5 every 28 days + IFN‐alpha 2b 10 MIU m(‐2) every other day (Group A)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Temozolomide 150 mg m(‐2) on days 1‐5 every 28 days + IFN‐alpha 2b fixed dose of 10 MIU every other day (Group B)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Patients with at least one complete remission
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Patients with at least one partial response
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Patients who completed at least three cycles of therapy with partial or complete response
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Major side effects of treatment
Number of subjects: 47
Study: 11359431

Group type: EXPERIMENTAL
Intervention: Budesonide (400 microg inhaled plus 200 microg intranasal)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg oral)
Number of subjects: 12
Study: 9217273

Group type: EXPERIMENTAL
Intervention: 1 ug/day of 1,25(OH)2D3 for 14 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2 ug/day of 1,25(OH)2D3 for 14 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7954251

Group type: EXPERIMENTAL
Intervention: Glutamine-supplemented TPN (40 g L-alanyl-L-glutamine, 26 g glutamine)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control TPN (without glutamine)
Number of subjects: 20
Study: 3325090

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 9
Study: 29211298

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (3 courses)
Number of subjects: 432
Study: 28375117

Group type: EXPERIMENTAL
Intervention: Amoebex (400mg)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Metronidazole (400mg)
Number of subjects: 184
Study: 25365012

Group type: EXPERIMENTAL
Intervention: Functional meat (FM)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control meat (CM)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Comparison between FM and CM
Number of subjects: 43
Study: 23385035

Group type: EXPERIMENTAL
Intervention: IV rocuronium 0.06 mg/kg
Number of subjects: 260

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 260
Study: 20492571

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 18822334

Group type: EXPERIMENTAL
Intervention: MEDI-534 vaccine
Number of subjects: 0
Study: 16386671

Group type: EXPERIMENTAL
Intervention: Inducible patients (standard definition)
Number of subjects: 593

Group type: COMPARATOR
Intervention: Noninducible patients
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Narrow inducibility definition
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Broad inducibility definition
Number of subjects: 593
Study: 12594152

Group type: EXPERIMENTAL
Intervention: Propofol 1%
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Propofol 2%
Number of subjects: 108
Study: 10802796

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (Cr)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 8635377

Group type: EXPERIMENTAL
Intervention: Albuterol (400 microg every 10 min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fenoterol (400 microg every 10 min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Albuterol (ED50F)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fenoterol (ED50F)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Albuterol and Fenoterol (Heart Rate)
Number of subjects: 8
Study: 1484773

Group type: EXPERIMENTAL
Intervention: Three-message group heard a tape containing the backward messages recorded three times in succession
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Six-message group heard a tape with the same backward messages recorded six times in succession
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group heard nonbackward recorded music
Number of subjects: 82
Study: 3883162

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 12
Study: 30791125

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) 40 μg/day
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Anastrozole (ATZ) 300 μg/day
Number of subjects: 216
Study: 29036427

Group type: EXPERIMENTAL
Intervention: Combined enalapril 10 mg and folic acid 0.8 mg tablet
Number of subjects: 3230

Group type: COMPARATOR
Intervention: Enalapril 10 mg tablet alone
Number of subjects: 3230

Group type: EXPERIMENTAL
Intervention: Time‐averaged diastolic blood pressure (DBP) of ≤80 mmHg
Number of subjects: 3230

Group type: EXPERIMENTAL
Intervention: Time‐averaged SBP of ≤130 mmHg
Number of subjects: 3230

Group type: COMPARATOR
Intervention: Time‐averaged SBP of 135 to ≤140 mmHg
Number of subjects: 3230
Study: 26871238

Group type: EXPERIMENTAL
Intervention: Morphine (5 mg 0.5% hyperbaric bupivacaine + 0.1 mg morphine)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Fentanyl (5 mg 0.5% hyperbaric bupivacaine + 25 µg fentanyl)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (5 mg 0.5% hyperbaric bupivacaine + physiologic saline)
Number of subjects: 90
Study: 23095095

Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard wound care therapies
Number of subjects: 0
Study: 23249443

Group type: EXPERIMENTAL
Intervention: Dentist-led strategy
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Teacher-led strategy
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Peer-led strategy
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Self-learning strategy
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 5
Study: 21060072

Group type: EXPERIMENTAL
Intervention: Ticagrelor 180-mg loading dose followed by 90 mg twice daily
Number of subjects: 7544

Group type: COMPARATOR
Intervention: Clopidogrel 300-mg loading dose followed by 75 mg daily
Number of subjects: 7544

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 7544

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 7544
Study: 17425224

Group type: EXPERIMENTAL
Intervention: Gaboxadol 5 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Gaboxadol 15 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 14673397

Group type: EXPERIMENTAL
Intervention: Levobupivacaine + fentanyl
Number of subjects: 28

Group type: COMPARATOR
Intervention: Ropivacaine + fentanyl
Number of subjects: 28
Study: 11087881

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg daily
Number of subjects: 8076

Group type: COMPARATOR
Intervention: Naproxen 500 mg twice daily
Number of subjects: 8076
Study: 8615705

Group type: EXPERIMENTAL
Intervention: Initial treatment with lovastatin
Number of subjects: 612

Group type: COMPARATOR
Intervention: Stepped-care regimen
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Costs of care
Number of subjects: 612
Study: 1307655

Group type: EXPERIMENTAL
Intervention: Low-dose antacids (Alugastrin and Alumag)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose antacids and ranitidine
Number of subjects: 0
Study: 6236738

Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg daily
Number of subjects: 28

Group type: COMPARATOR
Intervention: Indomethacin 25 mg t.i.d.
Number of subjects: 28
Study: 30985644

Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg
Number of subjects: 204

Group type: COMPARATOR
Intervention: Trichlormethiazide 1 mg
Number of subjects: 204
Study: 28045374

Group type: EXPERIMENTAL
Intervention: ILM peeling (P)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Non-ILM peeling (NP)
Number of subjects: 102
Study: 25887103

Group type: EXPERIMENTAL
Intervention: Preoperative endoscopic biliary drainage
Number of subjects: 106

Group type: COMPARATOR
Intervention: Preoperative percutaneous transhepatic biliary drainage
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 106
Study: 23664718

Group type: EXPERIMENTAL
Intervention: OU care with stress CMR
Number of subjects: 105

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 105
Study: 21613242

Group type: EXPERIMENTAL
Intervention: $100 incentive
Number of subjects: 3550

Group type: EXPERIMENTAL
Intervention: $50 incentive
Number of subjects: 3550

Group type: EXPERIMENTAL
Intervention: $2 preincentive
Number of subjects: 3550

Group type: EXPERIMENTAL
Intervention: Postal prenotification letter
Number of subjects: 3550

Group type: COMPARATOR
Intervention: No incentive
Number of subjects: 3550

Group type: EXPERIMENTAL
Intervention: Entry into a $200 lottery
Number of subjects: 3550
Study: 20122589

Group type: EXPERIMENTAL
Intervention: Mapleson A system at 10 L/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mapleson D system at 10 L/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Circle anesthesia system at 10 L/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mapleson A system at 5 L/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mapleson D system at 5 L/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Circle anesthesia system at 5 L/min
Number of subjects: 10
Study: 17316865

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) spray
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) spray after crossover
Number of subjects: 46
Study: 14665886

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Lidocaine/Bupivacaine
Number of subjects: 300
Study: 10852142

Group type: EXPERIMENTAL
Intervention: Targeted preventive strategies addressing six identified risk factors
Number of subjects: 852

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 852
Study: 8986845

Group type: EXPERIMENTAL
Intervention: Asperger syndrome (AS) patients rated for pedantic speech
Number of subjects: 17

Group type: COMPARATOR
Intervention: High-functioning autism (HFA) patients rated for pedantic speech
Number of subjects: 17
Study: 1479161

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg daily (doubled dose after 4 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ranitidine 300 mg twice daily (doubled dose after 4 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg twice daily (for refractory patients)
Number of subjects: 60
Study: 6464812

Group type: EXPERIMENTAL
Intervention: Assertion training treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo-counseling program
Number of subjects: 0
Study: 30612858

Group type: EXPERIMENTAL
Intervention: Cligosiban 100 mg once daily for 10 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cligosiban 400 mg once daily for 10 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cligosiban 800 mg once daily for 10 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cligosiban 1200 mg once daily for 10 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cligosiban 2400 mg once daily for 10 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30167856

Group type: EXPERIMENTAL
Intervention: Foley catheter
Number of subjects: 91

Group type: COMPARATOR
Intervention: Double balloon catheter
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Foley catheter (intrauterine fetal death)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Double balloon catheter (live fetuses)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Foley catheter (history of vaginal delivery)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Double balloon catheter (no history of vaginal delivery)
Number of subjects: 91
Study: 26821137

Group type: EXPERIMENTAL
Intervention: Hemi- or total hip arthroplasty
Number of subjects: 141
Study: 24220616

Group type: EXPERIMENTAL
Intervention: Decitabine 20 mg/m² once daily for 5 days every 4 weeks (n = 242)
Number of subjects: 485

Group type: COMPARATOR
Intervention: Treatment choice (supportive care or cytarabine 20 mg/m² once daily for 10 days every 4 weeks; n = 243)
Number of subjects: 485
Study: 22936892

Group type: EXPERIMENTAL
Intervention: EFV+FTC-TDF
Number of subjects: 1571

Group type: COMPARATOR
Intervention: EFV+3TC-ZDV
Number of subjects: 1571

Group type: EXPERIMENTAL
Intervention: ATV+DDI+FTC
Number of subjects: 1571
Study: 21182602

Group type: EXPERIMENTAL
Intervention: 30 mg mirtazapine
Number of subjects: 100
Study: 18684288

Group type: EXPERIMENTAL
Intervention: Remote magnetic navigation (RMN)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional (CON) manual approach
Number of subjects: 32
Study: 16183813

Group type: EXPERIMENTAL
Intervention: Protein intake of 3.3 g/100 kcal
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Protein intake of 3.0 g/100 kcal
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Protein intake of 2.7 g/100 kcal
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Protein intake greater than 2.7 g/100 kcal
Number of subjects: 77
Study: 12562576

Group type: EXPERIMENTAL
Intervention: Olanzapine + Reboxetine (4 mg/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Olanzapine + Placebo
Number of subjects: 26
Study: 10379448

Group type: EXPERIMENTAL
Intervention: Erlanger silver catheter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Statistical model analyzing first catheter only (independent data)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Statistical model analyzing several catheters from the same patient (dependent data)
Number of subjects: 0
Study: 8678065

Group type: EXPERIMENTAL
Intervention: Bicarbonate Dialysis (BD)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hemodiafiltration (HDF)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acetate-Free Biofiltration (AFB)
Number of subjects: 12
Study: 1904908

Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 31809349

Group type: EXPERIMENTAL
Intervention: Nanosecond Pulsed Electric Field Treatment (NPS)
Number of subjects: 58
Study: 31719604

Group type: EXPERIMENTAL
Intervention: Total adiponectin quartile (Q4)
Number of subjects: 1228

Group type: COMPARATOR
Intervention: High molecular weight (HMW) adiponectin quartile
Number of subjects: 1228
Study: 28963159

Group type: EXPERIMENTAL
Intervention: TiPEEK (polyetheretherketone cage with titanium coating)
Number of subjects: 40

Group type: COMPARATOR
Intervention: PEEK (polyetheretherketone cage without titanium coating)
Number of subjects: 40
Study: 26560511

Group type: EXPERIMENTAL
Intervention: THC (0.75 mg twice daily in blocks 1-3 and 1.5 mg twice daily in blocks 4-6)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 24162942

Group type: EXPERIMENTAL
Intervention: Manual based coping intervention (8 sessions delivered by supervised psychology graduates)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Manual based coping intervention
Number of subjects: 260

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 260
Study: 21831581

Group type: EXPERIMENTAL
Intervention: Intra-articular multimodal drug injection
Number of subjects: 286

Group type: COMPARATOR
Intervention: Normal saline solution (placebo)
Number of subjects: 286
Study: 20141383

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Recreation therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Attention-control group
Number of subjects: 80
Study: 17047021

Group type: EXPERIMENTAL
Intervention: T3 infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 10
Study: 16398435

Group type: EXPERIMENTAL
Intervention: Local thermotherapy with rabdosia liquid, starting from 1-2 months after operation, once tri-monthly for one year.
Number of subjects: 123

Group type: COMPARATOR
Intervention: Intravesical perfusion of mitomycin C, starting from 2 weeks after operation, once weekly for six times, thereafter once monthly for one year.
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Local thermotherapy with rabdosia liquid
Number of subjects: 123

Group type: COMPARATOR
Intervention: Intravesical perfusion of mitomycin C
Number of subjects: 123
Study: 12196768

Group type: EXPERIMENTAL
Intervention: Dye-spray (0.1% indigo carmine used to coat the entire colon during withdrawal from the cecum)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Control group (no dye)
Number of subjects: 259
Study: 9665616

Group type: EXPERIMENTAL
Intervention: Non-dominant (left) hand task in right handers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dominant (right) hand task in right handers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both hand tasks in left handers
Number of subjects: 0
Study: 8591624

Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (no fibrin glue)
Number of subjects: 26
Study: 2760254

Group type: COMPARATOR
Intervention: Dilevalol (single dose)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dilevalol (chronic treatment)
Number of subjects: 20
Study: 65039

Group type: EXPERIMENTAL
Intervention: Adriamycin plus bleomycin
Number of subjects: 34

Group type: COMPARATOR
Intervention: Cyclophosphamide plus vincristine
Number of subjects: 34
Study: 31719301

Group type: EXPERIMENTAL
Intervention: Anthropometry-based models (ASMM 1-ASMM 4) developed using height, weight, triceps skinfold thickness (TSFT), age, and menopausal status (MS) as independent variables.
Number of subjects: 332
Study: 29188863

Group type: EXPERIMENTAL
Intervention: Total baseline plasma homocysteine
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Total baseline plasma homocysteine in subjects with low baseline omega-3 index (< 4.72%)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Total baseline plasma homocysteine in subjects with high baseline omega-3 index
Number of subjects: 177
Study: 26004026

Group type: EXPERIMENTAL
Intervention: Mucogyne® applied 3 times a week for 84 days
Number of subjects: 47
Study: 23715873

Group type: EXPERIMENTAL
Intervention: Thiamine supplementation (3 × 100 mg/day for 6 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 20415525

Group type: EXPERIMENTAL
Intervention: Subcutaneous local anesthesia (LA)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Intravenous regional anesthesia (IVRA)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study: 19672237

Group type: EXPERIMENTAL
Intervention: Galantamine (8 mg daily for the 1st month, increasing to 16 mg daily; 6 patients received 24 mg from the 3rd month)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Galantamine with antipsychotic therapy (15 patients)
Number of subjects: 25
Study: 16540614

Group type: EXPERIMENTAL
Intervention: Single blastocyst-stage embryo (day 5)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Single cleavage-stage embryo (day 3)
Number of subjects: 351
Study: 15258329

Group type: EXPERIMENTAL
Intervention: New test (Cervical acid phosphatase - CAP)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Pap control (standard Pap test)
Number of subjects: 1500
Study: 10691900

Group type: EXPERIMENTAL
Intervention: Diet omitting known pseudoallergens for 6 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Diet omitting known pseudoallergens
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Oral challenge with food rich in pseudoallergens
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Double-blind exposure to food additives
Number of subjects: 50
Study: 9426670

Group type: EXPERIMENTAL
Intervention: Tumescent liposculpture combined with external ultrasound
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tumescent liposculpture alone
Number of subjects: 30
Study: 8224683

Group type: EXPERIMENTAL
Intervention: Sodium phosphate solution
Number of subjects: 100

Group type: COMPARATOR
Intervention: Polyethylene glycol-electrolyte lavage
Number of subjects: 100
Study: 2869210

Group type: EXPERIMENTAL
Intervention: Synthetic peptide vaccine (18-aminoacid E. coli heat-stable toxin and 26-aminoacid heat-labile toxin B subunit)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Synthetic peptide vaccine
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (preimmunisation titres)
Number of subjects: 13